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Abstract: 23 
This report describes the identification of a genetically confirmed linked heterosexual HIV superinfection 24 
(HIV-SI) where a chronically HIV-infected woman acquired a second strain of the virus from her 25 
husband.  Serum neutralizing antibody (NAb) responses were examined before and after the HIV-SI, in 26 
both the woman and her husband, against their homologous and heterologous viruses including the 27 
superinfecting strain.  The woman displayed a moderately potent and broad anti-HIV NAb response prior 28 
to superinfection, but did not possess NAb activity against the superinfecting strain.  This case highlights 29 
the unique potential of linked HIV-SI studies to examine natural protection from HIV infection.   30 
  31 
Background: 32 
 HIV-superinfection (HIV-SI) occurs when an HIV-infected individual acquires a new HIV strain 33 
that is phylogenetically distinct from their existing viral population[1].  The majority of studies examining 34 
HIV-SI have examined high-risk populations; however, HIV-SI also occurs at significant rates in the 35 
general HIV-infected population[1-4].  Screening for cases of HIV-SI in large population cohorts has 36 
allowed for the examination of immunological characteristics that may be associated with protection 37 
against HIV-SI by comparing superinfection cases to matched HIV-infected controls who do not become 38 
superinfected.  Of particular interest in these studies has been the potential role of pre-existing HIV-39 
specific neutralizing antibodies (NAb) in protecting against HIV-SI.  Two matched case control studies 40 
observed that individuals who became superinfected appear to have lower NAb responses compared to 41 
controls, but a larger study of female bar workers in Kenya found no association between pre-existing 42 
NAb and protection from HIV-SI[5-9].  An alternative approach for exploring HIV-SI risk is to examine 43 
HIV-infected couples who acquired their viruses from different sources, thereby making their viral 44 
populations phylogenetically unlinked[4, 10].  These couples can then be examined at multiple time 45 
points for a linked HIV-SI event if one or both members of the couple pass their virus onto their partner, 46 
which then allows for the examination of the underlying immune response to their partner’s viral 47 
population before and after the HIV-SI event[4, 10, 11].   48 
Methods:  49 
Participants in this study were enrolled in a General Population Cohort (GPC); established in 50 
1989 by the then MRC Programme on AIDS in rural Southwest Uganda (Supplementary Methods)[12]. 51 
Individuals in monogamous (n=15) and polygamous relationships (n=6) from the Rural Clinical Cohort in 52 
southwest Uganda previously identified as being HIV-infected, but virally unlinked by bulk HIV 53 
sequence analysis, were tested for occurrence of HIV-SI by examining longitudinal serum samples for 54 
each member of the partnership using a previously described next-generation sequencing (NGS) assay of 55 
three viral genomic regions (gag, pol, gp41; Supplementary Methods)[10, 13].  Individuals with 56 
successful NGS of two longitudinal samples for at least one genetic region whose corresponding partner 57 
also had NGS data available from the same genetic region were assessed for linked HIV-SI (Table S1). 58 
One such event was detected. 59 
For the linked HIV-SI case, serum samples from before and after the time of HIV-SI for both the 60 
female, and her male husband, were subjected to single-genome amplification (SGA) in order to generate 61 
full-envelope sequences (Fig. S1; Supplementary Methods).  For male samples prior to the female’s HIV-62 
SI event, full-length SGA was unsuccessful, therefore total RNA was amplified using universal primers 63 
and sequenced using a shotgun sequencing method (Supplementary Methods).  NGS amplicons specific 64 
for the HIV Env gene were matched to the SGA sequences from other time points to verify similarity.  65 
Full-length Env amplicons from SGA were subcloned or synthesized and used to generate Env-66 
pseudoviruses. All pseudoviruses were examined for functionality and neutralization susceptibility to 67 
known monoclonal antibodies, as well as a variety of subtype A and A/D serum from historic serum 68 
samples and non-superinfected Ugandans in the same cohort.  Env-pseudoviruses were tested for their 69 
neutralization susceptibility to their homologous serum, as well as their partner’s heterologous serum 70 
from before and after HIV-SI (Supplementary Methods).  Viral sequences are available in Genbank 71 
(accession numbers MG722983-MG724743).   72 
Results:  73 
Ten individuals had NGS data from at least one genomic region for two time points that matched 74 
the same region from their partner’s NGS data.  Of these ten, one case of a linked HIV-SI was identified. 75 
The case occurred in a polygamous relationship in which an HIV-infected uncircumcised male had four 76 
wives who were also HIV-positive (Table S1).  Longitudinal NGS data was available for both the male 77 
and one of his wives from the initial screen (Figure S1).  NGS data was available for the pol and gp41 78 
region from only one time point for two of his other three wives, and they were linked to their husband 79 
(Figure S2).  The fourth wife’s virus did not amplify for either time point examined.  The male was 80 
initially infected approximately four years prior to the HIV-SI event with a recombinant virus that 81 
contained HIV subtype D in the Pol region and subtype A in the gp41 region (Figure 1A and S2).  The 82 
female was also initially infected approximately four years before the HIV-SI event, and prior to marrying 83 
her husband, with a pure subtype A virus in both pol and gp41 (Figure 1A).  It was observed that she 84 
became superinfected, with a virus that was phylogenetically linked to her husband’s viral strain, between 85 
19-22 months after her initial sample (Figure S1).  During this three-month period, the woman also 86 
became pregnant, and although anti-retroviral therapy (ART) to prevent mother-to-child transmission was 87 
not available in this area of Uganda at this time (early 2000s), she later gave birth to a baby that did not 88 
become infected with HIV.   89 
Full-length viral Env sequences were obtained from the female partner immediately before HIV-90 
SI (Month 0, n=21) and when HIV-SI was first detected three months later (Month +3, n=10; Figure S4).  91 
Three of the viral sequences from this later sample were phylogenetically linked to the male’s viruses, 92 
thus representing the superinfecting strain (Figure 1B & S4). Full-length envelope sequences from the 93 
male partner 12 months after he superinfected the female were also generated (n=24, Figure S4). Full-94 
length Env sequences from the male SGA after HIV-SI contained regions from both subtype A and D, 95 
indicating a unique A/D recombinant, and corroborating the assertion that the NGS data from gag and pol 96 
came from the same virus (Figure S3). The male had no indication of HIV-SI between the two time points 97 
examined by NGS, or in any of the SGA sequences examined later (Figure S2).  Repeated attempts to 98 
amplify full-length envelopes from earlier time points in the male were unsuccessful; however, shotgun 99 
NGS analysis of viral RNA recovered from his serum sample at the time of HIV-SI (Month +0.3) 100 
identified one fragment with a 230 bp overlap into the 5’ end of the viral envelope. This fragment differed 101 
by only one non-synonymous nucleotide mutation from the three superinfecting strains found in the 102 
female after HIV-SI (Figure 2C).  103 
Full-length Env amplicons from SGA were subcloned or synthesized and used to generate Env-104 
pseudoviruses for both the female (Month0, n=2; Month +3 n=3 including one SI strain) and male (Month 105 
+12, n=9 only four were used for subsequent assays) (Figure 2C and S4)[14].  All pseudoviruses were 106 
examined for functionality and neutralization susceptibility to well-described anti-HIV monoclonal 107 
antibodies, as well as a variety of subtype A and A/D serum from historic serum samples and non-108 
superinfected Ugandans in the same cohort[15]. These pseudoviruses demonstrated varying susceptibility 109 
to the monoclonal antibodies and serum tested (Figure 2 & S5). Based on this susceptibility, all Env-110 
pseudoviruses from the couple were not unusually sensitive to neutralization, and had a tier-2 like 111 
phenotype.  112 
The serum from the female (Months -3,0,+3,+10) and the male (Months +0.3,+12) were tested for 113 
their neutralization activity against the couple’s Env-pseudoviruses (Figure 2).  The female’s serum 114 
samples prior to HIV-SI displayed moderate NAb activity against her homologous virus. However, her 115 
serum prior to HIV-SI and immediately post HIV-SI contained no detectable NAb activity to the 116 
superinfecting strain, and weak responses to her husband’s strains from one year later (Month +12) that 117 
were genetically similar to the superinfecting strain (Figure 2A).  Ten months post HIV-SI the female had 118 
developed a moderate response to the superinfecting strain (Figure 2).  In contrast, there was no increase 119 
in NAb response to the other male viruses from Month +12 (Figure 2).   120 
The male’s serum at the time of HIV-SI had no detectable neutralizing activity against his wife’s 121 
strains, and his NAb responses to those strains did not improve one-year post HIV-SI (Figure 2). 122 
However, his sera from one year after HIV-SI had high titer NAb activity against the superinfecting strain 123 
(Figure 2). 124 
Discussion: 125 
 This identification and characterization of a genetically confirmed case of a linked heterosexual 126 
HIV-SI event provides a unique opportunity to examine HIV-SI in an individual where her infecting 127 
partner is known. In this case, HIV-SI occurred in a chronically infected female who had moderately 128 
potent and broad anti-HIV NAb responses.  Despite this, she possessed no detectable NAb response to the 129 
superinfecting viral strain during the estimated window when HIV-SI occurred, which potentially could 130 
have protected her against the superinfecting strain.  This lack of response was not due to an inability to 131 
develop a NAb response to this strain since she developed a moderate NAb response to the SI virus 132 
approximately seven months after superinfection, as well as a low response to three of four other viruses 133 
isolated from her male partner.  It is interesting that the male possessed a very limited NAb response to 134 
the viruses tested, even after being infected for over 30 months at the time of HIV-SI.  However, like his 135 
female partner his NAb response to the superinfecting strain, which originally came from him, increased 136 
significantly 12 months after the superinfection occurred.   137 
There is a large body of preclinical data indicating that NAb can confer protective immunity 138 
against animal lentiviruses.  The data from this case report agree with the widely held concept that NAb 139 
are an important component of protective immunity against HIV infection, and thus a successful HIV 140 
vaccine should aim to elicit a broadly reactive NAb response[16].  As with any single case, these data are 141 
supportive, but not conclusive.  Also, this study was limited by the sample types (serum only) and 142 
volumes available, as this was a secondary analysis of a previous study performed over fifteen years ago.  143 
The limited sample volume for this couple precluded examining other interesting aspects of the humoral 144 
immune response that may play a role in protection against HIV-SI, as well as limiting the ability to fully 145 
characterize the neutralization breadth of the couple before and after HIV-SI. The totality of the data were 146 
also limited by the inability to amplify full envelope sequences from the male partner prior to HIV-SI.  147 
However, the superinfecting strain’s viral envelope sequence isolated from the woman at the time of HIV-148 
SI was almost identical to a fragment of envelope sequence taken from the man prior to HIV-SI, 149 
suggesting that this isolate is extremely similar to the superinfecting viral strain.   150 
  Notably, the male possessed no detectable NAb response to the female’s heterologous virus, yet 151 
he did not become superinfected.  This could be influenced by the possibility that NAb have no protective 152 
role against HIV-SI, the increased risk of male-to-female transmission compared to female-to male, or 153 
that he was protected by a different immunological response not examined here[8, 17].  In summary, this 154 
case demonstrates the exciting amount of potential information that even a small number of these types of 155 
cases could provide, and supports the need to further examine historic cohorts for linked HIV-SI events.   156 
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Figure 1: Sequencing results demonstrate a linked HIV-SI event: A) Neighbor-joining phylogenetic 169 
tree of consensus gp41 viral sequences (≥10 reads) derived from next-generation sequencing (NGS) of the 170 
female (Red) and male’s (Blue) initial time point (-19 months), as well as the female’s viral sequences 171 
immediately post HIV-SI (Month +3; Green) with the superinfecting viral strains clustering with the 172 
husband’s virus.  Number of repeated sequences represented by each NGS consensus sequence is shown 173 
at the end of the consensus identifier.  B) Neighbor-joining tree of full SGA derived viral envelopes used 174 
for pseudotyped viruses.  C) Neighbor-joining tree of 230 bp of the 5’ end of the viral envelope from the 175 
pseudotyped viral isolates aligned with the NGS shotgun-sequencing fragment from husband’s sample 176 
prior to HIV-SI (Orange).  The fragment clusters with the superinfecting strain found in his wife 177 
immediately after HIV-SI.  Distances are indicated for the tree by the scale at bottom, and samples are 178 
grouped with a selection of subtype reference sequences (black). Bootstrap values greater than 80 percent 179 
are indicated (1000 replicates). 180 
Figure 2: Female member’s sera did not neutralize superinfecting viral strain: A) Values in table 181 
indicate the dilution of the heat-inactivated serum required to block fifty percent of a standard infectious 182 
dose (ID50): weak (green), moderate (yellow), and strong (orange) neutralization values are highlighted.  183 
Along the top of the table are indicated time points of female and male sera, as well as a collection of sera 184 
from HIV-subtype A and A/D infected individuals.  The three columns to the left show information on 185 
Env-pseudoviruses tested, including the month and visit time point. The female SI virus (SI-Female 186 
Month+3_v2) is shown colored in green. Sera from individuals screened for linked superinfection are 187 
indicated by couple number and member ID (Table S1). To provide a benchmark for the varied levels of 188 
neutralization activity against autologous viruses, the male and female’s sera were also tested against a 189 
panel of six previously described HIV-pseudoviruses (Heterologous virus panel). The female’s serum 190 
samples prior to HIV-SI displayed a measurable NAb response to five of the six unassociated 191 
pseudoviruses, and the male’s serum at the time of HIV-SI was weakly neutralizing against all the 192 
pseudoviruses tested.  B) ID50 values of the female’s samples over time against the corresponding 193 
heterologous and homologous pseudoviruses are shown (Blue-male pseudoviruses, Red-female 194 
pseudoviruses, Green-superinfecting strain).  195 
 196 
Supporting Information Legends 197 
Table S1: Successful next-generation sequence screening data for Ugandan couples 198 
Figure S1: Timeline of viral load and sequencing of linked HIV-SI event 199 
Figure S2: NGS data for linked HIV-SI family.  200 
Figure S3: Viral envelope from the male was identified as an A/D recombinant.  201 
Figure S4: Neighbor-joining tree of full-length SGA derived viral envelopes from the male at month_+12 202 
and from his wife at month_0 and _+3 after the beginning of the superinfection window.  203 
Figure S5: Envelopes from male and female have a tier 2-like neutralization phenotype.  204 
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Supplementary Methods 
Study Participants: 
Participants in this study were enrolled in a General Population Cohort (GPC); 
established in 1989 by the then Medical Research Council Programme on AIDS in rural 
Southwest Uganda[1, 2]. The GPC initially enrolled approximately 5,000 adults drawn from a 
cluster of 15 villages and later in 1990, a random selection of one-third of seropositive adults 
identified in the initial GPC serosurvey round were invited to enroll into the Rural Clinical 
Cohort (RCC), previously called Natural History Cohort, as prevalent HIV cases[3]. Thereafter, 
all new HIV seroconverters were invited to enroll as incident cases. Participants enrolled in the 
RCC attend the study clinic every three months for clinical history, examination and blood 
sampling and HIV infected participants are encouraged to bring their partner(s) for voluntary 
counseling and testing and possible enrollment.  This study was approved by the Science and 
Ethics Committee of the Uganda Virus Research Institute and by the Uganda National Council 
for Science and Technology.  Clinical, epidemiological data and blood samples were obtained 
following informed consent. 
 
Next-generation sequencing to screen for HIV superinfection 
As reported previously, viral RNA was extracted from ~140 µL of the first and last serum 
samples available for each member of the couples, reverse-transcribed, and amplified in a 
nested-PCR format for a region of the viral p24 (~390 bp), reverse transcriptase (~530 bp) and 
gp41 (~324 bp) coding regions[4, 5].  Subject samples that amplified for both time points in at 
least one region were sequenced using the 454 DNA Sequencing platform (Roche, Branford, 
CT). Pools of samples were processed using emPCR Amplification Manual-Lib-L-LV–June 
2013(Roche Branford, CT) using 25% of the recommended amplification primer amount and a 
0.2 copy-per-bead ratio[4]. 
 The resulting sequencing reads were analyzed and similar sequences were combined into 
a single consensus sequence.  Consensus sequences that encompassed a cluster of at least ten 
individual, near-identical sequence reads were determined and used for all subsequent 
analyses[4].  All consensus sequences were examined and single consensus sequences that 
matched the prominent species for another sample in the same plate were removed as 
contamination.  Linked HIV superinfection (HIV-SI) was defined when a subject’s follow-up 
sample demonstrated two or more distinct consensus sequences forming a phylogenetic cluster 
that was of adequate genetic distance from the baseline sequences to rule out evolutionary drift 
from the individual’s initial consensus sequences, and that was phylogenetically linked to their 
partner’s viral sequences at their first sample time point [4].  The window period of possible 
HIV-SI was determined by NGS of all available serum samples between the first and last 
available sample for the superinfected individual. 
 
Single genome amplification (SGA), sequencing and cloning  
Single genome amplification (SGA), sequencing, and cloning of HIV-1 envelope genes 
were performed as reported previously [6]. Briefly, HIV-1 RNA was isolated from serum using 
the QiaAmp vRNA mini kit (Qiagen). HIV-1 RNA was then reverse transcribed to cDNA using 
SuperScript III Reverse Transcriptase (Life Technologies) and previously described clade A 
reverse primers nef 50 (5’-AGAGCTCCCTTGTAAGTCATTGG-3’) or nef24 
(5’TACTTGTGATTGCTCCATGT-3’) or newly synthesized nefvrc2 (5’-
CTTTCCCTTATAGCAGGCCATC-3’) [6, 7].  Subsequent PCR was performed under limiting 
dilution conditions, diluted to yield amplification in no more than 25% of wells. Nested PCR of 
HIV-1 env was performed with different primer sets as follows. First round PCR was performed 
either with primers previously described, vpr1 (5’- GATAGATGGAACAAGCCCCAG-3’) and 
nef24 (5’- TACTTGTGATTGCTCCATGT-3’) or newly designed primers nefvrc2 (5’- 
CTTTCCCTTATAGCAGGCCATC-3’) and vprvrc1 (5’- 
CACCTATGGCAGGAAGAAGCGGAG-3’) [6, 7]. Thermocycler conditions were 94°C for 2 
minutes followed by 35 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 4 
seconds with a final incubation at 68°C for 10 minutes. Second round PCR was performed with 
primers previously described, including vpr21a1 (5’- 
TAACCTAGACGCGTGGAATCACCCGGGAAGTCAGCCTACAACACCTTGTA 
-3’), vpr21a2 (5’-
TAACCTAGACGCGTGGAATCACCCGGGAAGCCGGCCTACAACACCTTGTA-3’), 
nef60a1 (5’-
CTTGTGGCGGCCGCATGTTTATCTAAATCTCGAGATACTGCTCCTACTCCTGGTGCTG
-3’), and nef60a2 (5’-
CTTGTGGCGGCCGCATGTTTAGCTAAATCTCGAGATACTGCTCCTACTCCTGCTGCTG
-3’), or newly designed primers including vprvrc5 (5’-
CACCAATAAGAGAAAGAGCAGAAGACAG-3’) and nefvrc5 (5’-
CTATRCTACTTTTTGACCACTTG-3’) [8]. Thermocycler conditions were 94°C for 2 minutes 
followed by 45 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 4 seconds with 
a final incubation at 68°C for 10 minutes.  The amplicons from envelope genes from single 
genome templates were directly sequenced by ACGT, Inc. (Germantown, MD). The full-length 
envelope sequences were assembled and edited using Geneious software.  
Envelope amplicons were cloned into the pcDNA 3.1 vector (directional) (Life 
Technologies) by re-amplification of SGA first round products using Phusion DNA polymerase 
(Agilent Technologies) with primers vprvrc1 (5’- CACCTATGGCAGGAAGAAGCGGAG-3’) 
and nefvrc5 (5’-CTATRCTACTTTTTGACCACTTG-3’). Cloned env genes were sequenced to 
confirm that they exactly matched the sequenced amplicon.  
SGA was successful for the female samples (0, +3 Months) and the male sample (+12 
Months). Of note, no amplicons were obtained from four earlier samples from the male (three 
time points pre-SI window and one in the SI-window). Three envelope sequences from the 
female that were amplified, but could not be subcloned (SI-Female Month+3_v1, SI-Female 
Month+3_v2, and SI-Female Month+3_v9) were codon optimized, synthesized, and then 
subcloned (GenScript, Piscataway, NJ).  Envelope clones were used to generate single round of 
replication Env-pseudoviruses, as described below.   
 The subtype of the Env sequences was determined using the RIP program via the website 
https://www.hiv.lanl.gov/content/sequence/RIP/RIP.html [9].  The male Env sequences were 
determined to be A/D recombinant, with 4 breakpoints in the rev-env region, using the RIP tool 
as well as analysis by jumping profile Hidden Markov Model via the website 
http://jphmm.gobics.de/jphmm.html [10]. 
  
Shotgun sequencing 
For male samples (-18, +0.3 Months), total RNA was extracted from serum using RNAzol RT 
(Molecular Research Center, Inc, Cincinnati, OH), according to the manufacturer’s protocol. 
RNA was fragmented, reversed transcribed using random hexamers and Illumina-ready libraries 
were generated based on Illumina’s TruSeq platform. The Illumina-ready libraries were 
sequenced by paired-end MiSeq 2x150 base pair reads. HIV contigs were generated by 
performing de novo assembly with the short-read transcript assembler, Trinity, from the Broad 
Institute.  The assembled contigs were then aligned against the “nt” database from NCBI using 
BLAST+.  Contigs that aligned to HIV reference sequences were extracted for further analysis. 
Only the +0.3 Months sample yielded a fragment that matched HIV sequence, corresponding to 
nt 6184-6453 in the genome (HxB standard) and spanning the 3' end of vpu and the 5' end of env.  
 
Pseudovirus production 
As described previously, env-pseudoviruses were produced by co-transfecting 293T cells with 
cloned viral envelope plasmids and a full length HIV clone with envelope deleted 
(SG3∆env)[11]. The pseudoviruses were characterized with a panel of 10 mAbs in the TZM-bl 
neutralization assay (described below), including VRC01, PGT121, PGT128, PGT145, 10E8, 
CAP256-VRC26.25, N123-VRC43.01, 17b, 447-52D, and F105. The env-pseudoviruses from 
the female and male samples were used to test the level of NAb neutralization from the male and 
female serum samples. 
A 6-virus heterologous panel was generated to test NAb breadth in the serum of the male 
and female. This panel included BG505.W6M.C2, KER2018.11, Q842.d12, Q461.e2, TRO.11, 
and DU422.01.  
 
Neutralization assays  
Neutralization assays were performed as previously described[11, 12]. Briefly, pseudovirus was 
mixed with serial dilutions of serum or monoclonal antibodies, incubated together for 30 
minutes, and then added to TZM-bl target cells which express luciferase upon infection. The data 
were calculated as a reduction in luminescence units compared with control wells, and reported 
as 50% inhibitory concentration (IC50) in micrograms per microliter for monoclonal antibodies, 
or 50% inhibitory dilution (ID50) for serum. 
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Supplementary Tables and Figure Legends 
Table S1: Successful next-generation sequence screening data for Ugandan couples 
 
-Male (M) and female (F) members of the couples are indicated; subtypes are indicated and were 
determined phylogenetically (M=multiple infections detected with subtypes of each variant population 
identified); (-) in the subtype column indicates that NGS for that genetic region was unsuccessful for that 
subject; (-) in the SI column indicates only one time point was successful for that genetic region. NGS 
was not successful for either member of couples 3, 6, 7, 13, 16, 18, 19, and 20.  The male from couple 9 
had evidence of a HIV-SI in the gp41 region.  The new superinfecting strain was not phylogenetically 
linked to any of his female partners, and therefore was determined to be unlinked.   
  
Couple 
Number
Partner 
idenity
Person years 
of follow-up
Gag 
subtype
Gag SI
Pol 
subtype
Pol SI
gp41 
subtype
gp41 SI Final SI status 
1 M 2.76 A No A No A No
1 F-1 N/A - - - - - -
2 M 1.50 D - - - - -
2 F-1 3.02 D - - - - -
2 F-2 1.50 C - - - - -
4 M 2.02 A No - - A No
4 F-1 1.02 - - - - A -
5 M 2.94 - - D - M (D/A) -
5 F-1 3.76 - - D No A No
5 F-2 3.75 - - A - M (D/D) -
5 F-3 5.48 - - D - A -
8 M 1.06 D No D No D No
8 F-1 2.47 D No D No D No
9 M 3.07 M (A/A) No A No A Yes Not linked SI
9 F-1 3.93 A - A - A -
9 F-2 6.32 - - - - - -
9 F-3 2.90 A - A - A -
10 M N/A D - D - A -
10 F-1 0.00 A No A No A No
11 M 5.51 - - - - A No
11 F-1 5.05 - - - - A -
12 M 1.19 - - A - - -
12 F-1 2.00 A No D No D No
14 M 0.95 D - D No D -
14 F-1 1.04 D - D - D -
15 M 6.24 - - D No A No
15 F-1 1.54 - - D - A -
15 F-2 4.99 D - D - A -
15 F-3 2.49 - - A - A Yes Linked SI
15 F-4 2.76 - - - - - -
17 M 2.90 - - - - - -
17 F-1 3.77 - - D No D No
21 M 6.52 D - D - - -
21 F-1 0.27 A No D No - -
Figure Legends 
Figure S1: Timeline of viral load and sequencing of linked HIV-SI event: The female’s (red) and 
male’s (blue) viral loads are indicated prior to and after the HIV-SI window (yellow box).  Samples where 
next-generation sequences were obtained are indicated by arrows (Red, Female; Blue, Male).  Samples 
where single genome amplification (SGA) sequencing was also successful are shown by arrows with solid 
fill, and the number of resulting functional pseudoviruses used for neutralization assays are indicated in 
boxes above (Green indicates superinfecting strain). 
Figure S2: NGS data for linked HIV-SI family. A) Neighbor-joining phylogenetic tree of consensus 
gp41 viral sequences (≥10 reads) derived from next-generation sequencing (NGS) of the male’s (Blue) 
initial time point (-19 months) and his follow-up time point (+56 months; Purple).  B) Neighbor-joining 
phylogenetic tree is shown including the male (Blue) and his wives’ initial gp41 NGS viral sequences 
(Female 1-Pink; Female 2-Orange, and Female 3-Red). C) Neighbor-joining phylogenetic tree is shown 
including both male sample time points (-19 months-Blue, and +56 months-Purple) and his wives’ pol 
NGS viral sequences (Female 1 +54 months-Pink; Female 2 +9 months-Orange, and Female 3 -19 
months-Red). Number of repeated sequences represented by each NGS consensus sequence is shown at 
the end of the consensus identifier.  Distances are indicated for the tree by the scale at bottom, and 
samples are grouped with a selection of subtype reference sequences (black).  
Figure S3: Viral envelope from the male was identified as an A/D recombinant. Subtype 
determination and breakpoint locations are shown and were calculated using jpHMM-HIV. Base pair 
locations are shown above and refer to HXB2 genome reference sequence. One representative sequence is 
shown. 
Figure S4: Neighbor-joining tree of full-length SGA derived viral envelopes from the male at 
month_+12 and from his wife at month_0 and _+3 after the beginning of the superinfection 
window.  Sequences that either could not be cloned (_nC), weren’t entry competent (_nE), or were not 
made into pseudoviruses (_nP) are indicated at the end of the sequence name. Sequences from the male 
that were made into fully functional pseudoviruses are shown (blue) with sequences not made into 
pseudoviruses also shown (light blue). Similarly, the wives’ primary viruses (red and pink), and 
superinfecting strains (green and light green) are shown.  Distances are indicated for the tree by the scale 
at bottom, and samples are grouped with a selection of subtype reference sequences (black).  
Figure S5: Envelopes from male and female have a tier 2-like neutralization phenotype. 
Neutralization susceptibility to monoclonal antibodies for pseudoviruses derived from the male and 
female couple members. Heat map showing the concentration of the neutralizing antibody required to 
block fifty percent of a standard infectious dose (IC50). Pseudoviruses used for other assays are shown in 
bold.     
 
A) B) C)
Figure 1:
0.87
1.0
1.0
1.0
0.82
0.97
0.97
1.0
1.0
Female Sera Male Sera Clade A/AD Sera Controls
Virus from 
Sample    
Pseudovirus Subtype -3 Months 0 Months +3 Months +10 Months +0.3 Months + 12 Months
CHAVI219 
2008
POC36633 
1995
POC44951 
1996 
APOS101 
2004
Uganda 
357139
Uganda 
191520
Uganda 
119601
Uganda 
355472
Uganda 
171950
Female 
0 Months
Female_Month0_v3 A 101 87 ND 681 <20 <20 102 <20 44 <20 69 72 112 62 78
Female_Month0_v17 A 124 135 ND 680 <20 <20 101 164 158 <20 124 112 180 121 108
Female 
+3 Months 
Female Month+3_v8 A 110 122 ND 263 <20 <20 72 68 199 <20 105 80 129 90 85
Female Month+3_v10 A 150 184 ND 181 <20 <20 51 43 84 <20 91 79 100 95 62
SI-Female Month+3_v2 AD <20 <20 <20 112 34 870 410 <20 <20 <20 <20 22 28 <20 <20
Male 
+12 Months
Male Month+12_v5 AD 60 60 54 62 60 125 782 <20 <20 35 <20 104 102 <20 <20
Male Month+12_v9 AD 30 39 ND 46 26 44 904 <20 <20 33 <20 123 153 <20 <20
Male Month+12_v14 AD <20 <20 <20 21 <20 44 478 <20 <20 36 <20 35 52 <20 <20
Male Month+12_v17 AD 27 24 ND 29 21 53 950 <20 <20 24 <20 143 271 <20 <20
Heterologous 
Virus Panel 
BG505.W6M.C2 A 62 35 ND 29 ND 29 721 <20 <20 62 30 <20 71 <20 <20
KER2018.11 A 143 230 ND 294 ND 24 351 <20 <20 55 26 <20 23 <20 20
Q842.d12 A 344 68 ND 344 ND 29 1240 79 116 36 151 109 211 101 137
Q461.e2 AD <20 <20 ND <20 ND <20 99 <20 <20 <20 <20 <20 <20 <20 <20
TRO.11 B 31 29 ND 34 ND 96 218 <20 <20 140 <20 33 58 <20 <20
DU422.01 C 166 27 ND 274 ND 25 77 111 116 45 121 74 151 76 87
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